Compile Data Set for Download or QSAR
Report error Found 106 Enz. Inhib. hit(s) with all data for entry = 12993
TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748608(US20250188037, Example 15)
Affinity DataIC50: 14.8nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748646(US20250188037, Example 65)
Affinity DataIC50: 15.1nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748620(US20250188037, Example 31)
Affinity DataIC50: 17.8nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748631(US20250188037, Example 45)
Affinity DataIC50: 20.9nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748633(US20250188037, Example 47)
Affinity DataIC50: 25.7nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748610(US20250188037, Example 18)
Affinity DataIC50: 26.3nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748606(US20250188037, Example 13)
Affinity DataIC50: 35.5nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748609(US20250188037, Example 16)
Affinity DataIC50: 36.3nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748602(US20250188037, Example 5)
Affinity DataIC50: 38.9nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748642(US20250188037, Example 57)
Affinity DataIC50: 38.9nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748619(US20250188037, Example 30)
Affinity DataIC50: 40.7nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748612(US20250188037, Example 22)
Affinity DataIC50: 40.7nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748615(US20250188037, Example 25)
Affinity DataIC50: 46.8nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748632(US20250188037, Example 46)
Affinity DataIC50: 51.3nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748617(US20250188037, Example 27)
Affinity DataIC50: 56.2nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748645(US20250188037, Example 64)
Affinity DataIC50: 56.2nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748614(US20250188037, Example 24)
Affinity DataIC50: 58.9nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748616(US20250188037, Example 26)
Affinity DataIC50: 70.8nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748641(US20250188037, Example 56)
Affinity DataIC50: 72.4nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748640(US20250188037, Example 55)
Affinity DataIC50: 74.1nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748613(US20250188037, Example 23)
Affinity DataIC50: 74.1nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748630(US20250188037, Example 44)
Affinity DataIC50: 87.1nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748600(US20250188037, Example 3)
Affinity DataIC50: 91.2nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748649(US20250188037, Example 69)
Affinity DataIC50: 102nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748647(US20250188037, Example 66)
Affinity DataIC50: 112nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748648(US20250188037, Example 68)
Affinity DataIC50: 115nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748629(US20250188037, Example 43)
Affinity DataIC50: 135nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748622((NB011692-080-002): 2-(2-cyanophenoxy)-2,2-difluor...)
Affinity DataIC50: 162nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748651(US20250188037, Example 71)
Affinity DataIC50: 166nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748643(US20250188037, Example 58)
Affinity DataIC50: 170nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748618(US20250188037, Example 29)
Affinity DataIC50: 186nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748624(US20250188037, Example 35)
Affinity DataIC50: 219nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748599(US20250188037, Example 1)
Affinity DataIC50: 219nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748625(US20250188037, Example 36)
Affinity DataIC50: 275nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748603(US20250188037, Example 6)
Affinity DataIC50: 282nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748639(US20250188037, Example 54)
Affinity DataIC50: 282nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748627(US20250188037, Example 41)
Affinity DataIC50: 295nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748611(US20250188037, Example 19)
Affinity DataIC50: 309nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748626(US20250188037, Example 37)
Affinity DataIC50: 324nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748650(US20250188037, Example 70)
Affinity DataIC50: 331nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748635(US20250188037, Example 49)
Affinity DataIC50: 347nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748601(US20250188037, Example 4)
Affinity DataIC50: 347nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748607(US20250188037, Example 14)
Affinity DataIC50: 407nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748604(US20250188037, Example 10)
Affinity DataIC50: 513nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748644(US20250188037, Example 62)
Affinity DataIC50: 562nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748623(US20250188037, Example 34)
Affinity DataIC50: 676nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748628(US20250188037, Example 42)
Affinity DataIC50: 813nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748605(US20250188037, Example 12)
Affinity DataIC50: 891nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748636(US20250188037, Example 50)
Affinity DataIC50: 1.32E+3nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM748637(US20250188037, Example 51)
Affinity DataIC50: 2.95E+3nMAssay Description:Test compounds are suspended in DMSO and then diluted in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA) plus 0.2 nM I-125 label...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

Displayed 1 to 50 (of 106 total ) | Next | Last >>
Jump to: